NZ544208A - N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
NZ544208A
NZ544208A NZ544208A NZ54420804A NZ544208A NZ 544208 A NZ544208 A NZ 544208A NZ 544208 A NZ544208 A NZ 544208A NZ 54420804 A NZ54420804 A NZ 54420804A NZ 544208 A NZ544208 A NZ 544208A
Authority
NZ
New Zealand
Prior art keywords
compound
formula
ring
compound according
exemplified
Prior art date
Application number
NZ544208A
Other languages
English (en)
Inventor
David Waterson
Maurice Raymond Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ544208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ544208A publication Critical patent/NZ544208A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ544208A 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyformamide compounds as metalloproteinase inhibitors NZ544208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
NZ544208A true NZ544208A (en) 2009-02-28

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ544208A NZ544208A (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (33)

Country Link
US (1) US7485644B2 (enExample)
EP (1) EP1644340B1 (enExample)
JP (1) JP4701167B2 (enExample)
KR (1) KR20060026440A (enExample)
CN (2) CN102229589A (enExample)
AR (1) AR044931A1 (enExample)
AT (1) ATE414063T1 (enExample)
AU (1) AU2004251104B2 (enExample)
BR (1) BRPI0411929A (enExample)
CA (1) CA2529468A1 (enExample)
CO (1) CO5650254A2 (enExample)
CY (1) CY1108757T1 (enExample)
DE (1) DE602004017733D1 (enExample)
DK (1) DK1644340T3 (enExample)
ES (1) ES2315675T3 (enExample)
HR (1) HRP20090009T3 (enExample)
IL (1) IL172615A0 (enExample)
IS (1) IS8257A (enExample)
MX (1) MXPA05013460A (enExample)
MY (1) MY138680A (enExample)
NO (1) NO20060444L (enExample)
NZ (1) NZ544208A (enExample)
PL (1) PL1644340T3 (enExample)
PT (1) PT1644340E (enExample)
RU (1) RU2351595C2 (enExample)
SA (1) SA04250224B1 (enExample)
SE (1) SE0301922D0 (enExample)
SI (1) SI1644340T1 (enExample)
TW (1) TW200524898A (enExample)
UA (1) UA81491C2 (enExample)
UY (1) UY28387A1 (enExample)
WO (1) WO2005000822A1 (enExample)
ZA (1) ZA200510458B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
HRP20110874T1 (hr) * 2005-10-26 2011-12-31 Merck Serono Sa Derivati sulfonamida i njihova uporaba za modulaciju metaloproteinaza
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
JP5808743B2 (ja) * 2010-07-08 2015-11-10 科研製薬株式会社 N−ヒドロキシホルムアミド誘導体およびそれを含有する医薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100597A3 (en) * 1998-01-30 2001-12-28 Darwin Discovery Ltd Cambridge Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
ES2281346T3 (es) * 1999-06-04 2007-10-01 Astrazeneca Ab Inhibidores de metaloproteinasas.
ATE553097T1 (de) * 2000-02-21 2012-04-15 Astrazeneca Ab Piperidin- und piperazin-substituierte n- hydroxyformamiden zur verwendung als metalloproteinaseinhibitoren
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2528317A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
AU2004251104A1 (en) 2005-01-06
UY28387A1 (es) 2005-01-31
AR044931A1 (es) 2005-10-12
JP4701167B2 (ja) 2011-06-15
IL172615A0 (en) 2006-04-10
PL1644340T3 (pl) 2009-04-30
WO2005000822A1 (en) 2005-01-06
KR20060026440A (ko) 2006-03-23
US20070197542A1 (en) 2007-08-23
SE0301922D0 (sv) 2003-06-27
CO5650254A2 (es) 2006-06-30
ES2315675T3 (es) 2009-04-01
PT1644340E (pt) 2009-01-02
CN1812974A (zh) 2006-08-02
CA2529468A1 (en) 2005-01-06
JP2007516164A (ja) 2007-06-21
TW200524898A (en) 2005-08-01
DE602004017733D1 (de) 2008-12-24
MY138680A (en) 2009-07-31
AU2004251104B2 (en) 2008-05-08
UA81491C2 (en) 2008-01-10
CN102229589A (zh) 2011-11-02
US7485644B2 (en) 2009-02-03
MXPA05013460A (es) 2006-03-09
RU2351595C2 (ru) 2009-04-10
CY1108757T1 (el) 2014-04-09
HK1086835A1 (en) 2006-09-29
HRP20090009T3 (en) 2009-02-28
IS8257A (is) 2006-01-23
EP1644340B1 (en) 2008-11-12
SA04250224B1 (ar) 2009-05-31
BRPI0411929A (pt) 2006-08-15
ZA200510458B (en) 2007-03-28
RU2005141058A (ru) 2006-07-27
CN1812974B (zh) 2011-06-29
NO20060444L (no) 2006-03-22
SI1644340T1 (sl) 2009-02-28
EP1644340A1 (en) 2006-04-12
ATE414063T1 (de) 2008-11-15
DK1644340T3 (da) 2009-02-02

Similar Documents

Publication Publication Date Title
CN101541789B (zh) 用作基质金属蛋白酶抑制剂的乙内酰脲衍生物
KR101280095B1 (ko) 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
US8129412B2 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
AU2004251104B2 (en) N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors
HK1086835B (en) N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors
HK1108435B (en) Hydantoin derivatives useful as metalloproteinase inhibitors

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed